ALNYLAM PHARMACEUTICALS, INC. Additional Paid-in Capital 2009-2025 | ALNY
Beta
What is ALNYLAM PHARMACEUTICALS, INC.'s current additional paid-in capital?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual additional paid-in capital for 2025 was $7.51B, a 1.66% increase from 2024. ALNYLAM PHARMACEUTICALS, INC. additional paid-in capital for the quarter ending December 31, 2025 was $7.51B.
What was ALNYLAM PHARMACEUTICALS, INC.'s additional paid-in capital in 2024?
ALNYLAM PHARMACEUTICALS, INC. annual additional paid-in capital for 2024 was $7.39B, a 8.47% increase from 2023.
What was ALNYLAM PHARMACEUTICALS, INC.'s additional paid-in capital in 2023?
ALNYLAM PHARMACEUTICALS, INC. annual additional paid-in capital for 2023 was $6.81B, a 5.52% increase from 2022.
What is ALNYLAM PHARMACEUTICALS, INC.'s 5-year additional paid-in capital CAGR?
ALNYLAM PHARMACEUTICALS, INC. additional paid-in capital grew at a compound annual growth rate (CAGR) of 5.88% from FY2020 to FY2025, going from $5.64B to $7.51B over 5 years.
Additional Paid-in Capital History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR+5.9%
FY2020
$5.64B
→
FY2025
$7.51B
0910111213141516171819202122232425
5 years selected
Additional Paid-in Capital History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $7.51B | +1.7% | 10-K |
| FY2024 | $7.39B | +8.5% | 10-K |
| FY2023 | $6.81B | +5.5% | 10-K |
| FY2022 | $6.45B | +6.5% | 10-K |
| FY2021 | $6.06B | +7.3% | 10-K |
| FY2020 | $5.64B | +8.5% | 10-K |
| FY2019 | $5.20B | +24.6% | 10-K |
| FY2018 | $4.18B | +5.8% | 10-K |
| FY2017 | $3.95B | +51.3% | 10-K |
| FY2016 | $2.61B | +4.1% | 10-K |
| FY2015 | $2.51B | +36.0% | 10-K |
| FY2014 | $1.84B | +117.8% | 10-K |
| FY2013 | $846.2M | +35.4% | 10-K |
| FY2012 | $624.9M | +20.5% | 10-K |
| FY2011 | $518.7M | +3.7% | 10-K |
| FY2010 | $500.4M | +5.0% | 10-K |
| FY2009 | $476.7M | - | 10-K |
Company: ALNYLAM PHARMACEUTICALS, INC.Ticker: ALNYSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →